Allscripts Announces New Share Repurchase Program
May 26 2021 - 8:01AM
Business Wire
Allscripts Healthcare Solutions announced today that its Board
of Directors has approved a new share repurchase program under
which Allscripts may purchase up to $350 million of its common
stock. The new share repurchase program does not have a termination
date.
The new share repurchase program replaces the previously
existing share repurchase program, which authorized Allscripts to
repurchase $300 million of its common stock through December 31,
2021. Allscripts repurchased the entire amount available under the
prior program.
"Our strong balance sheet and financial performance enable us to
expand our share repurchase program, which remains an attractive
component of our capital deployment strategy," said Rick Poulton,
Allscripts President and Chief Financial Officer.
Allscripts plans to repurchase shares from time to time in the
open market, through transactions that may be characterized as
derivatives (including accelerated share repurchases), or in
privately negotiated transactions, subject to market conditions.
There is no guarantee as to the exact number of shares or value
that will be repurchased under the stock repurchase program, and
Allscripts may discontinue purchases at any time. Whether
Allscripts makes any repurchases will depend on many factors,
including but not limited to its business and financial
performance, the business and market conditions at the time,
including the price of Allscripts shares, and other factors that
management considers relevant.
About Allscripts Allscripts (NASDAQ: MDRX) is a leader in
healthcare information technology solutions that advance clinical,
financial and operational results. Our innovative solutions connect
people, places and data across an Open, Connected Community of
Health™. Connectivity empowers caregivers to make better decisions
and deliver better care for healthier populations. To learn more,
visit www.allscripts.com, Twitter, YouTube and
It Takes a Community: The Allscripts Blog.
© 2021 Allscripts Healthcare, LLC and/or its affiliates. All
Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are
trademarks of Allscripts Healthcare, LLC and/or its affiliates. All
other products are trademarks of their respective holders, all
rights reserved. Reference to these products is not intended to
imply affiliation with or sponsorship of Allscripts Healthcare, LLC
and/or its affiliates.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the federal
securities laws. Statements regarding future events or
developments, our future performance, as well as management's
expectations, beliefs, intentions, plans, estimates or projections
relating to the future are forward-looking statements with the
meaning of these laws. These forward-looking statements are subject
to a number of risks and uncertainties. As a result, no assurances
can be given that any of the events anticipated by the
forward-looking statements will transpire or occur, or if any of
them do so, what impact they will have on our results of operations
or financial condition. See our Annual Report on Form 10-K for 2020
and other public filings with the SEC for a further discussion of
these and other risks and uncertainties applicable to our business.
The statements herein speak only as of their date and we undertake
no duty to update any forward-looking statement whether as a result
of new information, future events or changes in expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526005114/en/
Investors: Stephen Shulstein
312-386-6735 stephen.shulstein@allscripts.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Apr 2023 to Apr 2024